Title:
COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/088385
Kind Code:
A1
Abstract:
The present invention relates to a compound for degrading an EGFR protein and the use thereof. Specifically, the present invention relates to a compound as represented by formula (I), and the definitions of each group and each substituent are as described in the description. The present invention further relates to the use of the compound in the preparation of a drug for regulating the activity of an EGFR tyrosine kinase or treating EGFR-related diseases, particularly non-small cell lung cancer.
Inventors:
LIANG APENG (CN)
WU YUSHENG (CN)
CHEN SHAOQING (CN)
LI JUN (CN)
HAN SHUNXUN (CN)
DONG SHENGLI (CN)
NIU CHENGSHAN (CN)
WU YUSHENG (CN)
CHEN SHAOQING (CN)
LI JUN (CN)
HAN SHUNXUN (CN)
DONG SHENGLI (CN)
NIU CHENGSHAN (CN)
Application Number:
PCT/CN2022/132632
Publication Date:
May 25, 2023
Filing Date:
November 17, 2022
Export Citation:
Assignee:
TYK MEDICINES INC (CN)
International Classes:
A61K31/427; C07D401/12; A61K31/496; A61K31/506; C07D401/02; C07D401/14; C07D417/12
Domestic Patent References:
| WO2020092662A1 | 2020-05-07 | |||
| WO2020172655A1 | 2020-08-27 | |||
| WO2021127561A1 | 2021-06-24 | |||
| WO2022012622A1 | 2022-01-20 | |||
| WO2022068849A1 | 2022-04-07 | |||
| WO2022171123A1 | 2022-08-18 | |||
| WO2022194269A1 | 2022-09-22 | |||
| WO2022228547A1 | 2022-11-03 | |||
| WO2022228556A1 | 2022-11-03 |
Foreign References:
| CN110204532A | 2019-09-06 | |||
| CN112321566A | 2021-02-05 | |||
| CN113735828A | 2021-12-03 | |||
| CN115304606A | 2022-11-08 | |||
| KR20220035014A | 2022-03-21 | |||
| TW202216686A | 2022-05-01 |
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF: